Co-Authors
This is a "connection" page, showing publications co-authored by Ioannis Trougakos and Meletios Dimopoulos.
Connection Strength
5.172
-
Comparative kinetics of SARS-CoV-2 anti-spike protein RBD IgGs and neutralizing antibodies in convalescent and naïve recipients of the BNT162b2 mRNA vaccine versus COVID-19 patients. BMC Med. 2021 08 23; 19(1):208.
Score: 0.963
-
Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications. J Biomed Sci. 2021 Jan 12; 28(1):9.
Score: 0.924
-
The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment. Blood Cancer J. 2021 08 02; 11(8):138.
Score: 0.240
-
Kinetics of Anti-SARS-CoV-2 Antibody Responses 3 Months Post Complete Vaccination with BNT162b2; A Prospective Study in 283 Health Workers. Cells. 2021 07 30; 10(8).
Score: 0.240
-
Low neutralizing antibody responses in WM, CLL and NHL patients after the first dose of the BNT162b2 and AZD1222 vaccine. Clin Exp Med. 2021 Jul 20.
Score: 0.239
-
Antibody Response After Initial Vaccination for SARS-CoV-2 in Patients With Amyloidosis. Hemasphere. 2021 Aug; 5(8):e614.
Score: 0.239
-
Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose. Blood. 2021 07 01; 137(26):3674-3676.
Score: 0.238
-
High Prevalence of Anti-PF4 Antibodies Following ChAdOx1 nCov-19 (AZD1222) Vaccination Even in the Absence of Thrombotic Events. Vaccines (Basel). 2021 Jul 01; 9(7).
Score: 0.238
-
Comparison of neutralizing antibody responses against SARS-CoV-2 in healthy volunteers who received the BNT162b2 mRNA or the AZD1222 vaccine: Should the second AZD1222 vaccine dose be given earlier? Am J Hematol. 2021 09 01; 96(9):E321-E324.
Score: 0.237
-
Low titers of SARS-CoV-2 neutralizing antibodies after first vaccination dose in cancer patients receiving checkpoint inhibitors. J Hematol Oncol. 2021 05 31; 14(1):86.
Score: 0.237
-
Age-dependent and gender-dependent antibody responses against SARS-CoV-2 in health workers and octogenarians after vaccination with the BNT162b2 mRNA vaccine. Am J Hematol. 2021 07 01; 96(7):E257-E259.
Score: 0.235
-
Seroprevalence of Antibodies against SARS-CoV-2 among the Personnel and Students of the National and Kapodistrian University of Athens, Greece: A Preliminary Report. Life (Basel). 2020 Sep 21; 10(9).
Score: 0.226
-
Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis. Blood Cancer J. 2018 05 24; 8(5):46.
Score: 0.192
-
Molecular responses to therapeutic proteasome inhibitors in multiple myeloma patients are donor-, cell type- and drug-dependent. Oncotarget. 2018 Apr 03; 9(25):17797-17809.
Score: 0.190
-
Milder degenerative effects of Carfilzomib vs. Bortezomib in the Drosophila model: a link to clinical adverse events. Sci Rep. 2017 12 19; 7(1):17802.
Score: 0.187
-
Novel Nested-Seq Approach for SARS-CoV-2 Real-Time Epidemiology and In-Depth Mutational Profiling in Wastewater. Int J Mol Sci. 2021 Aug 07; 22(16).
Score: 0.060
-
Systemic IL-15, IFN-?, and IP-10/CXCL10 signature associated with effective immune response to SARS-CoV-2 in BNT162b2 mRNA vaccine recipients. Cell Rep. 2021 08 10; 36(6):109504.
Score: 0.060
-
Accurate SARS-CoV-2 seroprevalence surveys require robust multi-antigen assays. Sci Rep. 2021 03 23; 11(1):6614.
Score: 0.058
-
Recovery of Innate Immune Cells and Persisting Alterations in Adaptive Immunity in the Peripheral Blood of Convalescent Plasma Donors at Eight Months Post SARS-CoV-2 Infection. Microorganisms. 2021 Mar 06; 9(3).
Score: 0.058
-
SARS-CoV-2 Infection Is Asymptomatic in Nearly Half of Adults with Robust Anti-Spike Protein Receptor-Binding Domain Antibody Response. Vaccines (Basel). 2021 Mar 02; 9(3).
Score: 0.058
-
Molecular mechanisms of carfilzomib-induced cardiotoxicity in mice and the emerging cardioprotective role of metformin. Blood. 2019 02 14; 133(7):710-723.
Score: 0.050